Lipidomics Profile Changes of Type 2 Diabetes Mellitus with Acute Myocardial Infarction

Abstract EN

The morbidity and mortality of cardiovascular disease (CVD)/acute myocardial infarction (AMI) of type 2 diabetes mellitus (T2DM) patients are extremely higher than those without T2DM.

Biomarkers can be used to predict the occurrence of acute myocardial infarction, thus effectively reducing the incidence of CVD events, particularly in T2DM patients.

Lipids have been shown to be biomarkers and potential therapeutic targets for human diseases.

The aim of our study was to investigate the prognostic value of lipid biomarkers for predicting AMI in T2DM patients.

A total of 420 subjects were recruited in this research.

Liquid Chromatography-Electrospray Ionization-Quadrupole Time of Flight-Mass Spectrometer- (LC-ESI-QTOF-MS-) and Liquid Chromatography/Mass Spectrometer- (LC/MS-) based metabolomic methods were applied to characterize metabolic profiles in each plasma sample.

In the first untargeted set, 40 T2DM patients with AMI, 40 T2DM patients without AMI, and 40 control subjects were gender- and age-matched.

Eight lipid metabolites showed a significant difference among three groups.

Then, in the second set, targeted metabolic profiling assays for these 8 lipid biomarker concentrations in plasma were performed; another 100 T2DM patients with AMI, 100 T2DM patients without AMI, and 100 control subjects were selected independently.

Receiver operating characteristic (ROC) curves were constructed, and the area under the ROC curves (AUC) was calculated to determine the potential biomarkers.

ROC curve analysis showed that the AUC value of lysophosphatidylcholine (LysoPC) 18:0 is more than 0.7, indicating that LysoPC 18:0 may be a potential sensitive and specific biomarker for T2DM with AMI.

The changed plasma concentrations of lipids were significantly associated with T2DM with AMI, which showed great value to be biomarkers, though it requires a prospective cohort study for further validation.